Relationship of Apolipoproteins A-1 and B, and Lipoprotein(a) to Cardiovascular Outcomes
Top Cited Papers
- 1 October 2013
- journal article
- research article
- Published by Elsevier BV in Journal of the American College of Cardiology
- Vol. 62 (17), 1575-1579
- https://doi.org/10.1016/j.jacc.2013.06.051
Abstract
No abstract availableFunding Information
- National Heart, Lung, and Blood Institute (U01-HL-081616, U01-HL-081649)
This publication has 10 references indexed in Scilit:
- HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatmentEuropean Heart Journal, 2013
- Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin TherapyThe New England Journal of Medicine, 2011
- Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring StudyJournal of Lipid Research, 2011
- Lipoprotein(a) as a cardiovascular risk factor: current statusEuropean Heart Journal, 2010
- Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular MortalityJAMA, 2009
- Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial InfarctionJAMA, 2009
- Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary eventsNature Reviews Cardiology, 2009
- Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery diseaseNature Genetics, 2009
- Effects of Lowering Elevated LDL Cholesterol on the Cardiovascular Risk of Lipoprotein(a)JAMA, 1995
- Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a)Clinical Chemistry, 1995